10 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Apr 2038. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Apr 2038
Next term end
8
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2038 · High confidence
Also notable
Ends May 2038 · High confidence
Also notable
Ends Oct 2039 · High confidence
Photobiomodulation Therapy to Reduce the Effects of Fibromyalgia
US 10,744,337
The most cited patent in this portfolio, cited by 24 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2038.
Restructuring Neural Pathways in the Brain with a Combination of Transcranial Therapies
US 10,758,739
The earliest of the three still in force, granted 2020 and renewed since. Its term ends first, in 2038.
Photobiomodulation Therapy to Treat a Degenerative Condition of the Retina And/Or the Optic Nerve
US 11,253,722
The newest of the three, granted 2022. It anchors the portfolio to 2039, later than anything else here.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 15, 2027The maintenance fee for Photobiomodulation Therapy to Treat a Degenerative Condition of the Retina And/Or the Optic Nerve (US 11,724,123) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 8 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Photobiomodulation Therapy to Treat a Degenerative Condition of the Retina And/Or the Optic Nerve | 2 in force | to Oct 2039 |
| Photobiomodulation Therapy to Reduce the Effects of Fibromyalgia | 2 in force | to Apr 2038 |
| Systems and Methods for Preserving And/Or Enhancing Respiratory Function | 1 in force | to Aug 2043 |
| Photobiomodulation Therapy to Improve Functional Mobility of Stroke Survivors | 1 in force | to Jul 2042 |
| Photobiomodulationtherapy for Urinary Incontinence | 1 in force | to Sep 2039 |
Patents held now
Soonest term end first.
Showing 1 to 10 of 10
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,744,337 | Photobiomodulation Therapy to Reduce the Effects of Fibromyalgia In force · High confidence | In force | High confidence | |
| US 11,590,355 | Photobiomodulation Therapy to Reduce the Effects of Fibromyalgia In force · High confidence | In force | High confidence | |
| US 10,758,739 | Restructuring Neural Pathways in the Brain with a Combination of Transcranial Therapies In force · High confidence | In force | High confidence | |
| US 11,426,600 | Photobiomodulation Therapy to Delay Dystrophy Progression In force · Medium confidence | In force | Medium confidence | |
| US 11,179,573 | Photobiomodulationtherapy for Urinary Incontinence In force · Medium confidence | In force | Medium confidence | |
| US 11,253,722 | Photobiomodulation Therapy to Treat a Degenerative Condition of the Retina And/Or the Optic Nerve In force · High confidence | In force | High confidence | |
| US 11,724,123 | Photobiomodulation Therapy to Treat a Degenerative Condition of the Retina And/Or the Optic Nerve In force · High confidence | In force | High confidence | |
| US 11,077,314 | System and Method for Treating Patients Requiring Mechanical Ventilation In force · High confidence | In force | High confidence | |
| US 12,296,187 | Photobiomodulation Therapy to Improve Functional Mobility of Stroke Survivors In force · High confidence | In force | High confidence | |
| US 12,636,514 | Systems and Methods for Preserving And/Or Enhancing Respiratory Function In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 10: 3 applications pending. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.